Estrella Immunopharma, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
| For the Three Months Ended | ||||
|---|---|---|---|---|
| March 31, · March 31, | ||||
| 2025 · 2024 | ||||
| Cash Flows from Operating Activities: | ||||
| Net loss | $(2,104,311) | $(469,530) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 159,095 | - | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other receivable | 201,066 | (4,862) | ||
| Prepaid expenses - related party | - | (3,500,000) | ||
| Accounts payable - related party | 9,553 | (77,076) | ||
| Other payables and accrued liabilities | (83,916) | (181,166) | ||
| Accrued liability - related party | 1,356,666 | (2,000) | ||
| Franchise tax payable | (4,134) | - | ||
| Net cash used in operating activities | (465,981) | (4,234,634) | ||
| Cash Flows from Financing Activities: | ||||
| Purchase of treasury stock | (29,462) | (84,091) | ||
| Net cash used in financing activities | (29,462) | (84,091) | ||
| Net Change in Cash | (495,443) | (4,318,725) | ||
| Cash at beginning of the period | 916,916 | 9,046,015 | ||
| Cash at end of the period | $421,473 | $4,727,290 | ||
| Supplemental Cash Flow Information | ||||
| Cash paid for income tax | $13 | $ | - | |
| Cash paid for interest | $ | - | $ | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.